Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
|Articles|October 20, 2014
Creating a dry eye protocol
In his second installment for his Optometry Times blog, The Schachter Factor, Dr. Scott Schachter discusses his protocol for diagnosing and treating dry eye patients in his practice.
Advertisement
In his second installment for his Optometry Times blog, Schachter Factor, Dr. Scott Schachter discusses his protocol for diagnosing and treating
Check out Dr. Schachter's first installment in his blog, where
Advertisement
Related to this article
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
4
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
5